Advancing discovery through Alluvi research
Alluvi Labs develops and evaluates premium peptides, Alluvi supplements,
All products are produced exclusively
for controlled research and development purposes, guided by science.
Not for human or veterinary consumption.
what is retatrutide
Retatrutide is an investigational peptide medication being studied for the treatment of obesity, overweight, and type 2 diabetes. It is designed as a triple hormone receptor agonist, targeting the GLP-1, GIP, and glucagon receptors to help regulate appetite, improve blood sugar control, and increase energy expenditure. This multi-target approach has made retatrutide one of the most closely watched therapies in metabolic research.
Clinical trials have shown promising results, including significant weight loss and improvements in metabolic health among participants. However, retatrutide remains under clinical investigation and has not yet received broad regulatory approval for general medical use. Researchers continue to evaluate its long-term safety, effectiveness, and potential role in treating obesity and related metabolic conditions through ongoing Phase 3 studies.
alluvi healths
Retatrutide – Pre-Filled Pen Evaluation
Not for human or veterinary consumption.
of stability, compound behaviour, and injector system performance.
Not for human or veterinary consumption.
Track. Dose. Progress.
The Alluvi app supports wellness goals with smart tracking, log nutrition, monitor weight, and stay consistent through a modern mobile dashboard.
Recovery Meets Routine
Daily gummy supplements crafted for sleep, stress support, and muscle recovery, for rest and protein for strength, all in a clean, delicious form
Power-Up in a Gummy
A delicious way to fuel your body with protein and creatine – Alluvi Gummy Bears are a quick, convenient solution to stay on top of daily nutrients. No scoops. No shakes. Just results.
No prep. No hassle. Just precision dosing.
Alluvi pens are supplied ready-to-use – no mixing, no guesswork.
Developed for controlled research applications, each unit features fixed pre-measured volumes to support consistency and reliability during laboratory evaluation.
Not for human or veterinary consumption.
Proven Data. Backed by Research.
Published studies have investigated GLP-1 multi-agonist compounds under controlled conditions.
Alluvi supplies Retatrutide pens exclusively for laboratory research and development.
Not for human or veterinary consumption.
All figures are derived from third party published studies and are shown only for academic context. All Alluvi products are supplied strictly for laboratory research purposes.
22.5%
Reference value drawn from published research on GLP-1 multi-agonist compounds.
Provided strictly as scientific context.
Participants consumed fewer calories per day without being instructed to diet – driven by decreased appetite and satiety signaling.
Provided strictly as scientific context.
28%
Reported value in published research relating to GLP-1 multi-agonist compounds.
Provided strictly as a scientific reference point
18.3 KG
Average weight loss during clinical trial period of 48 weeks on high-dose Retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.